Skip to main content
Premium Trial:

Request an Annual Quote

OliX Licenses AMD Drug to YuYu Pharma

Premium

NEW YORK (GenomeWeb) – Korean RNAi drug developer OliX Pharmaceuticals, formerly known as Biomolecular Therapeutics, announced today that it has licensed its siRNA-based age-related macular degeneration drug to YuYu Pharma.

The drug, called OLX301, comprises OliX's proprietary self-delivering siRNAs. Under the terms of the arrangement, YuYu will take over the drug's development, manufacturing, and commercialization. In exchange, OliX is eligible to receive milestone payments based on the drug's development and regulatory approval, as well as tiered royalties on product sales.

Additional terms of the deal were not disclosed.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.